NovoCure Ltd.
370 articles about NovoCure Ltd.
-
NovoCure Rlease: Pharma Announces Preliminary Fourth Quarter And Full Year 2016 Operating Statistics
1/10/2017
-
NovoCure Release: Company To Report Fourth Quarter And Full Year 2016 Financial Results
1/10/2017
-
NovoCure’s Optune (NovoTTF-100A) Approved In Japan For The Treatment Of Newly Diagnosed Glioblastoma
12/19/2016
-
NovoCure Presents Second Cohort Of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel And Gemcitabine May Be Safe As First-Line Treatment And May Improve One-Year Survival Rate Of Patients With Advanced Pancreatic Canc
12/13/2016
-
NovoCure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel May Be Safe As First-Line Treatment And May Improve Survival Of Patients With Recurrent Ovarian Cancer
12/13/2016
-
Long-Term Analysis Of All 695 Patients Enrolled In NovoCure’s Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results And Demonstrates Superior Two- And Four-Year Survival Rates
11/18/2016
-
NovoCure Presents Interim STELLAR Results At IASLC Suggesting Treatment With Tumor Treating Fields Plus Chemotherapy May Extend Survival Of Patients With Mesothelioma
11/17/2016
-
NovoCure Announces 38 Presentations On Tumor Treating Fields At 21st Annual Scientific Meeting Of The Society Of Neuro-Oncology
11/7/2016
-
NovoCure Reports Third Quarter 2016 Financial Results And Provides Company Update
11/2/2016
-
NovoCure Release: CNS Oncology Publishes Tumor Treating Fields Treatment Planning And Patient Follow-up Guidelines In Glioblastoma
9/19/2016
-
NovoCure’s Executive Chairman William Doyle To Present On Tumor Treating Fields At New York Academy Of Sciences’ Symposium On Bioelectronic Medicine
9/15/2016
-
Two Institutions Publish Independent Data On NovoCure’s Tumor Treating Fields
9/14/2016
-
Long-term Analysis Of All 695 Patients Enrolled In NovoCure’s Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Confirms Superior Progression Free And Overall Survival Seen In The Trial’s Interim Analysis
9/12/2016
-
NovoCure Release: International Journal Of Cancer Publishes Data Showing Tumor Treating Fields In Combination With Paclitaxel Is Therapeutically Effective Against Ovarian Cancer Cells In Vitro And In Vivo
9/1/2016
-
NovoCure Converts More Than 500 U.S. Patients To Second Generation Optune Within Four Weeks Of FDA Approval On July 13
8/16/2016
-
NovoCure To Present At Upcoming Investor Conferences
8/9/2016
-
NovoCure To Host Research And Development Day On Dec. 12, 2016
7/28/2016
-
NovoCure Reports Second Quarter 2016 Financial Results and Provides Company Update
7/28/2016
-
NovoCure Release: National Comprehensive Cancer Network Guidelines Recommend Optune As A Standard Treatment Option For Newly Diagnosed Glioblastoma
7/26/2016
-
NovoCure Snags FDA Approval for Second Generation Optune System
7/14/2016